**Kentucky Department for Medicaid Services**

# Pharmacy and Therapeutics Advisory Committee Recommendations

**March 16, 2006 Meeting**

**This chart provides a summary of the final PDL selections that were made by the Secretary for Health and Family Services as a result of the Pharmacy and Therapeutics Advisory Committee meeting of March 16, 2006**.

| | Description of Recommendation | Final PDL Decision |
|---|---|---|
| #1 | **Insulin**<br>**1.** The insulin agents are considered clinically equivalent in safety and efficacy.<br>**2.** DMS to prefer one brand of human insulin per class (basal long-acting, rapid-acting, and short-acting, insulin for use in pumps, mixed preparations and insulin delivery systems) based upon economic evaluation.<br>**3.** Lantus will be retained as a preferred basal long-acting insulin with the option to add other products in the class based upon economic evaluation.<br>**4.** Recommendations on Exubera to be tabled for review at a future meeting.<br>**5.** Byetta will require PA via electronic step-edit.<br>**6.** Symlin will require PA.<br>**7.** DMS to require PA for pen delivery systems for patients unable to manipulate vials/syringes (eyesight, dexterity, comprehension).<br>**8.** For any new chemical entity in the insulin class, require a PA until reviewed by the P & T Advisory Committee. | Recommendations Approved<br><br>PDL Selections<br>NOVOLOG<br>NOVOLOG mix 70/30<br>NOVOLIN 70/30<br>NOVOLIN N<br>NOVOLIN R<br><br>LANTUS<br>LEVEMIR |
| #2 | **Flouroquinolones**<br>**1.** All agents in the quinolone class are equivalent in efficacy within generations.<br>**2.** DMS to prefer generic 2nd generation quinolones.<br>**3.** Branded 2nd generation quinolones will require PA.<br>**4.** DMS to prefer two branded 3rd generation quinolones, one of which must be either Avelox or Levaquin and the other to be preferred based upon economic evaluation.<br>**5.** If Tequin is selected as a preferred 3rd generation quinolone, a diabetes safety edit must be implemented.<br>**6.** For any new chemical entity in the quinolone class, require a PA until reviewed by the P&T Advisory Committee. | Recommendations Approved<br><br>PDL Selections<br>2nd generation<br>CIPROFLOXACIN<br>OFLOXACIN<br>3rd generation<br>AVELOX<br>LEVAQUIN |

# Pharmacy and Therapeutics Advisory Committee Recommendations

**March 16, 2006 Meeting**